AOD-9604 Safety Profile and Potential Side Effects Safety data from over 900 clinical trial participants provides comprehensive information about AOD-9604s tolerability, side effect profile, and important contraindications
Tesamorelin is an FDA-approved synthetic analog of GHRH with human RCT data demonstrating roughly 15 to 18 percent reductions in visceral adipose tissue in HIV-associated lipodystrophy
Patients with active infections, certain autoimmune conditions, active malignancy, or pregnancy are typically not candidates and these are screened at consultation
View Article European Journal of Pharmacology (1999) "Pharmacological characterisation of Ipamorelin, a new growth hormone secretagogue." View Article Growth Hormone & IGF Research (1999) "Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats." View Article
They are listed here as a reference for researchers investigating IGF-1 LR3
GHRH receptor agonists and ghrelin-receptor agonists can produce complementary pituitary signaling